Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* History of migraine for more than12 months prior to screening~* Migraine frequency: ≥ 4 and ≤ 14 migraine days per month in each of the 3 months prior to screening and during baseline phase~* Headache frequency: \< 15 headache days per month (with \> 50% of the headache days being migraine days) in each of the 3 months prior to screening and during baseline phase~* Demonstrated at least 80% compliance with the eDiary during baseline phase~Exclusion Criteria:~* Older than 50 years of age at migraine onset~* History of cluster headache or basilar or hemiplegic migraine headache~* Unable to differentiate migraine from other headaches~* No therapeutic response with \> 2 of the following eight medication categories for prophylactic treatment of migraine after an adequate therapeutic trial. Medication categories are:~  * Category 1: Divalproex sodium, sodium valproate~ * Category 2: Topiramate~ * Category 3: Beta blockers (for example: atenolol, bisoprolol, metoprolol, nadolol, nebivolol, pindolol, propranolol, timolol)~ * Category 4: Tricyclic antidepressants (for example: amitriptyline, nortriptyline, protriptyline)~ * Category 5: Venlafaxine, desvenlafaxine, duloxetine, milnacipran~ * Category 6: Flunarizine, verapamil~ * Category 7: Lisinopril, candesartan~ * Category 8: Butterbur, feverfew, magnesium (≥ 600 mg/day), riboflavin (≥ 100 mg/day)~* Overuse of acute migraine medications in any month during the 3 months prior to screening or during screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.
- Erenumab 7 mg QM (Type: EXPERIMENTAL): Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.
- Erenumab 21 mg QM (Type: EXPERIMENTAL): Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.
- Erenumab 70 mg QM (Type: EXPERIMENTAL): Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.
- CHU Substudy: Erenumab 140 mg PFS (Type: EXPERIMENTAL): Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
- CHU Substudy: Erenumab 140 mg AI/Pen (Type: EXPERIMENTAL): Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using an autoinjector/pen (AI)/pen) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).

Based on this trial design, predict the completion outcome and termination type (if applicable).